Israel's State Comptroller Investigates GSF

24 July 1994

Israel's State Comptroller is currently investigating the financial collapse of the General Sick Fund, which provides health care for about 70% of the population (Marketletter June 27), and may issue a special report.

At a session of the parliamentary state control committee, Finance minister Avraham Shochat and the Secretary-General of the histadrut, Haim Ramon, welcomed the probe, which could also lead to a parliamentary investigation. The Comptroller is considering claims that politically-motivated considerations by mr Shochat and the Histadrut, before its elections in May, were instrumental in the GSF's problems.

This announcement comes straight after the publication of a report by the Comptroller on the implementation of the GSF recovery plan agreed in March 1993 by the Fund, the histadrut and the Treasury, to be implemented during 1993-95. The agreement outlined what the three parties would each contribute in order to make up 1993's anticipated deficit of NIS1.12 billion ($395 million).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight